Exane BNP Paribas analyst Navann Ty upgraded Revance to Neutral from Underperform with a $20 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVNC:
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Revance price target lowered to $40 from $44 at Needham
- 3 Best Stocks to Buy Now, 8/9/2023, According to Top Analysts
- Revance price target lowered to $41 from $48 at H.C. Wainwright
- Revance sees FY23 adjusted operating expenses $320M-$340M